ReviewOxford open immunology2026
Therapeutic potential of TAM receptors in autoimmune diseases: insights from original studies.
Review in Oxford open immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- AXL at the nexus of therapeutic resistance, tumor vascularization, and immune evasion in cancer.iScience · 2026Review
- Receptor-Ligand Biomarker Profile in Ankylosing Spondylitis: Associations BetweenLife (Basel, Switzerland) · 2026Article
- TAM receptor tyrosine kinases as potential mediators of the non-lytic spread of non-enveloped viruses.Biochemical Society transactions · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
TAM receptors, composed of Tyro3, Axl, and Mertk, belong to the receptor tyrosine kinase family and are activated by binding of their cognate ligands, Gas6 and Pros1. These receptor-ligand interactions mediate critical physiological processes, including the maintenance of immunological equilibrium, thrombocyte aggregation and subsequent thrombus development, apoptotic cellular debris clearance, homeostatic regulation of endothelial and vascular smooth muscle cells, and erythrocyte production. Perturbations in TAM signaling cascades have been shown to compromise the clearance of apoptotic cells, leading to persistent inflammatory responses that can contribute to the development of various autoimmune pathologies, including multiple sclerosis, rheumatoid arthritis, Sjögren's syndrome, and systemic lupus erythematosus. We retrieved and reviewed only the primary studies addressing the roles of TAM receptors and their ligands in selected autoimmune diseases from Google Scholar, Scopus, Web of Science, and PubMed. The critical roles of TAM receptors in immune homeostasis and apoptotic cell clearance are well established. However, findings from several primary studies discussed in this review further emphasized that the loss of TAM receptor function in these processes significantly contributes to the pathogenesis and progression of autoimmune diseases. Herein, we highlight the role of TAM receptors in several autoimmune diseases, suggesting that TAM receptors are potential biomarkers for monitoring disease prognosis and therapeutic targets to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.